Compositions comprising polynucleotides encoding TACI-immunoglobulin fusion proteins and methods for producing the same
Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor, have proven usefulness in both basic research and as therapeutics. The present invention provides improved soluble transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptors.
1. A nucleic acid molecule construct encoding a fusion protein, comprising:
(a) a first polynucleotide encoding a transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety, wherein the TACI receptor moiety consists of amino acid residues 30 to 154 of SEQ ID NO:2 and wherein the TACI receptor moiety binds at least one of ZTNF2 or ZTNF4; and,
(b) a second polynucleotide encoding an immunoglobulin moiety that comprises a C H2 and a C H3 domain;
wherein said first and said second polynucleotide encode said fusion protein.
2. The nucleic acid molecule construct of claim 1 , wherein said nucleic acid molecule construct is operably linked to a promoter that directs transcription of the encoded fusion protein.
3. The nucleic acid molecule construct of claim 1 , further comprising a third polynucleotide encoding a secretory sequence.
4. The nucleic acid molecule construct of claim 1 , wherein the immunoglobulin moiety is an IgG1 Fc fragment that comprises a disulfide linked heavy chain hinge region, a C H2 domain and a C H3 domain.
5. An expression vector comprising the nucleic acid molecule construct of claim 1 .
6. A host cell comprising the nucleic acid molecule construct of claim 1 .
7. A nucleic acid molecule construct encoding a fusion protein, comprising:
(a) a first polynucleotide encoding a transmembrane activator and calcium modulator and cyclophilin ligand-interactor (TACI) receptor moiety, wherein the TACI receptor moiety consists of amino acid residues 30 to 110 of SEQ ID NO:2 and wherein the TACI receptor moiety binds at least one of ZTNF2 or ZTNF4; and,
(b) a second polynucleotide encoding an immunoglobulin moiety that comprises a C H2 and a C H3 domain;
wherein said first and said second polynucleotide encode said fusion protein.
8. The nucleic acid molecule construct of claim 7 , wherein said nucleic acid molecule construct is operably linked to a promoter that directs transcription of the encoded fusion protein.
9. The nucleic acid molecule construct of claim 7 , further comprising a third polynucleotide encoding a secretory sequence.
10. The nucleic acid molecule construct of claim 7 , wherein the immunoglobulin moiety is an IgG1 Fc fragment that comprises a disulfide linked heavy chain hinge region, a C H2 domain and a C H3 domain.
11. The nucleic acid molecule construct of claim 7 , wherein the encoded fusion protein has an amino acid sequence comprising the secreted form of the amino acid sequence of SEQ ID NO:54.
12. The nucleic acid molecule construct of claim 11 , wherein said nucleic acid molecule construct is operably linked to a promoter that directs transcription of the encoded fusion protein.
13. The nucleic acid molecule construct of claim 7 , wherein the TACI-immunoglobulin fusion protein comprises the amino acid sequence of SEQ ID NO: 54, wherein the optimized tPA (otPA) leader sequence (SEQ ID NO:25) has been removed.
14. The nucleic acid molecule construct of claim 13 , wherein said nucleic acid molecule construct is operably linked to a promoter that directs transcription of the encoded fusion protein.
15. An expression vector comprising the nucleic acid molecule construct of claim 7 .
16. An expression vector comprising the nucleic acid molecule construct of claim 11 .
17. An expression vector comprising the nucleic acid molecule construct of claim 13 .
18. A host cell comprising the nucleic acid molecule construct of claim 7 .
19. A host cell comprising the nucleic acid molecule construct of claim 11 .
20. A host cell comprising the nucleic acid molecule construct of claim 13 .
21. A method of expressing a fusion protein comprising culturing a host cell comprising the nucleic acid molecule construct of claim 2 under conditions that allow for the expression of said fusion protein.
22. The method of claim 21 further comprising isolating said fusion protein.
23. A method of expressing a fusion protein comprising culturing a host cell comprising the nucleic acid molecule construct of claim 8 under conditions that allow for the expression of said fusion protein.
24. The method of claim 23 , further comprising isolating said fusion protein.
25. A method of expressing a fusion protein comprising culturing a host cell comprising the nucleic acid molecule construct of claim 12 under conditions that allow for the expression of said fusion protein.
26. The method of claim 25 further comprising isolating said fusion protein.
27. A method of expressing a fusion protein comprising culturing a host cell comprising the nucleic acid molecule construct of claim 14 under conditions that allow for the expression of said fusion protein.
28. The method of claim 27 further comprising isolating said fusion protein.